stockrowMBX Biosciences, Inc.
- EPS
- −34.5%
- Free cash flow
- −29.7%
Quarter to June 2026, against a year earlier
Follow MBX
Alert me
MBX Biosciences, Inc. (MBX) Return on invested capital
MBX Biosciences, Inc.'s return on invested capital over the twelve months to 30 June 2026 was 0.00%, down 0.0 percentage points from fiscal 2025 (0.00%). That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | — |
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| ADMA ADMA Biologics Inc compare | 48.0% |
| CLDX Celldex Therapeutics, Inc. compare | 0.00% |
| RCUS Arcus Biosciences, Inc. compare | 0.00% |
| MBX MBX Biosciences, Inc. | 0.00% |
| PHVS Pharvaris N.V. compare | 0.00% |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −21.3% |
| NAMS NewAmsterdam Pharma Company N.V. compare | −23.1% |
| RXRX Recursion Pharmaceuticals, Inc. compare | −88.5% |
| XNCR Xencor, Inc. compare | −288.7% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)